Prime Medicine develops therapies using prime editing, a gene editing technology that enables a wide range of DNA modifications with high precision. The company was founded by Drs. David Liu and Andrew Anzalone, pioneers of the prime editing approach. Prime is investigating prime editing for multiple diseases, including cystic fibrosis (CF), and is advancing preclinical work to deliver gene editing cargo to lung cells that produce CFTR. The company is pursuing multiple CF strategies, including a “hotspot” approach for small corrections and PASSIGE for large gene insertions, intended to reduce the need for mutation-specific therapies. Current development is focused on the CF nonsense mutation G542X, a prevalent mutation with no available therapies. Financial support for this work includes prior and additional commitments from the Cystic Fibrosis Foundation to fund preclinical development and delivery research. Prime Medicine develops therapies based on a gene editing technology called prime editing and was founded by researchers who pioneered that approach. The company is investigating whether prime editing could treat several diseases, including cystic fibrosis, by inserting DNA that codes for the CFTR gene. Prime is advancing two platform technologies for CF: “hotspot,” for smaller corrections to specific CFTR mutations, and PASSIGETM, for large gene insertions that could work across many mutations. The company has already used hotspot to correct the G542X nonsense CFTR mutation in the lab and plans to extend that work to other mutation clusters. Prime is also investigating lipid nanoparticle delivery to address challenges delivering genetic therapies to the lungs. The company’s current activities for CF are at the preclinical research stage. Prime Medicine is a Cambridge, MA biotechnology company focused on developing therapies using Prime Editing. Its core platform uses a prime editor protein (a Cas nickase fused to a reverse transcriptase) together with pegRNAs to search for and replace disease‑causing DNA sequences without producing double‑strand breaks. The company is advancing multiple drug discovery programs targeting liver, eye, ex‑vivo hematopoietic stem cell, and neuro‑muscular indications. Leadership includes CEO Keith Gottesdiener, MD; CSO Jeremy Duffield, MD, PhD; and scientific founders David R. Liu, PhD, and Andrew Anzalone, MD, PhD. Prime Medicine intends to use recent funding to progress toward clinical indications and to expand and enhance its platform capabilities. It expects to employ more than 100 full‑time employees as it scales development.

Total raised

$354M

Funding rounds

4

Latest round

Equity

Latest activity

Jul 2025